Adcendo’s ADCE-D01 Receives the US FDA’s Fast Track Designation to Treat Soft Tissue Sarcoma


Shots:

  • The US FDA has granted FTD to ADCE-D01 for the treatment of soft tissue sarcoma (STS)
  • ADCE-D01 is being evaluated in P-I/II (ADCElerate1/EUCT) dose escalation & expansion study as a monotx. for metastatic &/or unresectable STS, with enrolment ongoing in the US & EU
  • ADCE-D01 is an ADC targeting uPARAP & conjugated to the P1021 (topoisomerase I inhibitor) that demonstrated strong anti-tumor activity in mesenchymal tumor preclinical models, incl. STS, with favourable safety

Ref: Adcendo| Image: Adcendo| Press Release

Related News:- Boehringer Ingelheim Reports the US FDA’s Approval of Jascayd (Nerandomilast) for Idiopathic Pulmonary Fibrosis

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *